PUBLISHER: The Business Research Company | PRODUCT CODE: 1945347
PUBLISHER: The Business Research Company | PRODUCT CODE: 1945347
Implantable cardiac rhythm management devices are small battery-operated devices that are surgically inserted inside the body and connected to the heart, playing a crucial role in maintaining and managing heart rhythm.
The primary devices in the category of implantable cardiac rhythm management devices include cardiac resynchronization therapy, defibrillators, and pacemakers. Cardiac resynchronization therapy (CRT) is a specialized treatment designed for severe cardiac rhythm issues. These devices find applications in various conditions such as bradycardia, tachycardia, and others, and are utilized in hospitals, specialty cardiac centers, and other medical settings.
Tariffs are impacting the implantable cardiac rhythm management device market by increasing costs of imported microelectronics, batteries, sensors, leads, and specialized manufacturing equipment used in pacemakers and defibrillators. Cardiac care centers in North America and Europe are most affected due to reliance on imported components, while Asia-Pacific faces cost pressures in device production and export. These tariffs are raising device prices and impacting hospital procurement decisions. However, they are also encouraging domestic manufacturing, regional supply chain diversification, and innovation in cost-optimized cardiac rhythm management devices.
The implantable cardiac rhythm management device market research report is one of a series of new reports from The Business Research Company that provides implantable cardiac rhythm management device market statistics, including implantable cardiac rhythm management device industry global market size, regional shares, competitors with a implantable cardiac rhythm management device market share, detailed implantable cardiac rhythm management device market segments, market trends and opportunities, and any further data you may need to thrive in the implantable cardiac rhythm management device industry. This implantable cardiac rhythm management device market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The implantable cardiac rhythm management device market size has grown strongly in recent years. It will grow from $17.7 billion in 2025 to $18.89 billion in 2026 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to increasing prevalence of cardiac arrhythmias, rising aging population, expansion of cardiac care facilities, growing adoption of implantable pacemakers and defibrillators, improvements in cardiac device reliability.
The implantable cardiac rhythm management device market size is expected to see strong growth in the next few years. It will grow to $24.91 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to increasing adoption of smart implantable devices, rising focus on remote patient monitoring, expansion of AI-enabled rhythm analysis, growing demand for minimally invasive cardiac procedures, increasing healthcare investments in cardiac care infrastructure. Major trends in the forecast period include increasing adoption of remote cardiac monitoring capabilities, rising use of advanced battery technologies, growing integration of wireless cardiac devices, expansion of minimally invasive implantation techniques, enhanced focus on device longevity and reliability.
The rising incidence of cardiac disorders is anticipated to significantly enhance the growth of the implantable cardiac rhythm management devices market. Cardiac disorders refer to conditions that impact the heart or blood vessels. Implantable cardiac rhythm management devices are designed to assist patients with heart failure and diminished left ventricular function by improving systolic function through the resynchronization of heart contractions and restoring normal rhythm during life-threatening rapid ventricular arrhythmias. As a result, the growing prevalence of cardiac disorders will drive demand for these devices. For instance, in October 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, in 2023, cardiovascular disease claimed 919,032 lives, accounting for one in every three deaths. Coronary heart disease remained the most prevalent form of heart disease, and notably, about one in six deaths from cardiovascular diseases occurred among adults younger than 65 years. Therefore, the increasing prevalence of cardiac disorders is a key factor propelling the growth of the implantable cardiac rhythm management devices market.
The growing aging population is expected to drive the expansion of the implantable cardiac rhythm management devices market in the coming years. An aging population refers to a demographic trend in which a significant share of a country's residents are older, resulting in a higher average population age. Implantable cardiac rhythm management devices are widely used among older adults to treat and manage various cardiac conditions. For example, in January 2024, the Population Reference Bureau, a US-based nonprofit organization, reported that the number of Americans aged 65 and above is projected to increase from 58 million in 2022 to 82 million by 2050, representing a 47% rise. Additionally, this age group's proportion of the total population is expected to grow from 17% to 23% over the same period. Consequently, the increasing aging population is fueling the growth of the implantable cardiac rhythm management devices market.
Major companies in the implantable cardiac rhythm management devices market prioritize the launch of innovative products such as implantable cardiac defibrillators. In October 2023, MicroPort CRM, a France-based manufacturer, launched the ULYS Implantable Cardioverter Defibrillator (ICDs) and INVICTA defibrillation implantable devices. The ULYS ICD integrates cutting-edge technology with minimal energy consumption, featuring the AutoMRI function and PARAD arrhythmia discrimination algorithm. The INVICTA defibrillation lead consistently senses electrical signals from the right ventricle, providing pacing therapy if the heart rate is too low.
Major companies operating in the implantable cardiac rhythm management device market are Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, Biotronik SE & Co. KG, MicroPort Scientific Corporation, LivaNova PLC, Japan Lifeline Co Ltd, Lepu Medical Technology Beijing Co Ltd, Shree Pacetronix Ltd, Osypka Medical GmbH, Sorin Group Italia Srl, Medico SpA, Vitatron Holding BV, Pacetronix Ltd, CardioElectronica SA, Imricor Medical Systems Inc, Impulse Dynamics plc, Kardium Inc, Cortrium ApS, EBR Systems Inc
North America was the largest region in the implantable cardiac rhythm management device market in 2025. The regions covered in the implantable cardiac rhythm management device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the implantable cardiac rhythm management device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The implantable cardiac rhythm management devices market consists of sales of the leadless pacemaker, insertable cardiac monitor, cardiac leads, and subcutaneous implantable defibrillator (S-ICD). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Implantable Cardiac Rhythm Management Device Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses implantable cardiac rhythm management device market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for implantable cardiac rhythm management device ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The implantable cardiac rhythm management device market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.